Back

Corrigendum to: Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial

European Heart Journal

11 October 2019
Organised by: Logo
Read full article
ESC Journals
You may be interested in
thumbnail
Congress Presentation
Non-vitamin K antagonist oral anticoagulants are safe and effective alternatives to warfarin across subgroups by renal function: results from Danish registries
2 September 2019
thumbnail
Congress Presentation
Influence of heart failure and chronic kidney disease on cardiovascular outcome in patients with atrial fibrillation - insights from a cohort study of 7,412 patients
26 August 2023
thumbnail
Congress Presentation
Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE
2 September 2019
thumbnail
Congress Presentation
Impact of kidney function overestimation by creatinine compared to cystatin C in patients with atrial fibrillation
12 April 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources